Colon and rectum cancer screening coverage in Europe in Latvia
Latvia: Colon and rectum cancer screening coverage in Europe was 28.0% in 2025. ▲ Rising
Colon and rectum cancer screening coverage in Europe in Latvia, 2009–2025
Source: Eurostat (2026) – with minor processing by Our World in Data. Measured in %.
Analysis
Latvia recorded 28.0% for colon and rectum cancer screening coverage in europe in 2025. That is the highest value across all 17 years on record.
The figure is up 5.7% on the previous year and up 156.9% over ten years.
Over the whole period, colon and rectum cancer screening coverage in europe in Latvia peaked at 28.0% in 2025 and was at its lowest, 7.0%, in 2009.
Latvia ranks 16th of 20 countries on this measure, in the bottom quarter.
The long-run direction has been consistently rising across the 17 years of available data.
Colon and rectum cancer screening coverage in Europe in Latvia, year by year
| Year | % | Change |
|---|---|---|
| 2009 | 7.0% | — |
| 2010 | 7.6% | +8.9% |
| 2011 | 7.1% | -6.3% |
| 2012 | 7.6% | +7.6% |
| 2013 | 9.6% | +26.3% |
| 2014 | 10.6% | +9.9% |
| 2015 | 10.9% | +2.9% |
| 2016 | 11.8% | +8.3% |
| 2017 | 13.4% | +13.6% |
| 2018 | 16.0% | +19.4% |
| 2019 | 15.0% | -6.2% |
| 2020 | 13.3% | -11.3% |
| 2021 | 19.2% | +44.4% |
| 2022 | 19.3% | +0.5% |
| 2023 | 25.9% | +34.2% |
| 2024 | 26.5% | +2.3% |
| 2025 | 28.0% | +5.7% |
Latvia compared with similar countries
- Latvia's 28.0% is below the median for Europe & Central Asia, which is 39.2%, 71% of the median. (19 countries reporting)
- Latvia's 28.0% is below the median for high income countries, which is 46.6%, 60% of the median. (16 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 7.0% | 7.0% | 7.0% | 1 |
| 2010s | 11.0% | 7.1% | 16.0% | 10 |
| 2020s | 22.0% | 13.3% | 28.0% | 6 |
Countries ranked near Latvia
More health data for Latvia
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.3876 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,593 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -6.17 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0202 units per person (2025)
- Population ages 00-04, male, annual growth rate -6.02 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is colon and rectum cancer screening coverage in europe in Latvia?
- Colon and rectum cancer screening coverage in europe in Latvia was 28.0% in 2025, according to Eurostat (2026) – with minor processing by Our World in Data.
- What is the highest colon and rectum cancer screening coverage in europe recorded in Latvia?
- The highest recorded value was 28.0% in 2025.
- What is the lowest colon and rectum cancer screening coverage in europe recorded in Latvia?
- The lowest recorded value was 7.0% in 2009.
- How does Latvia rank for colon and rectum cancer screening coverage in europe?
- Latvia ranks 16th out of 20 countries with data for 2025.
- Is colon and rectum cancer screening coverage in europe rising or falling in Latvia?
- Over the last ten years it is up 156.9%. The long-run trend across the full record is rising.
- Where does this Latvia data come from?
- The figures come from Eurostat (2026) – with minor processing by Our World in Data, published as part of Colon and rectum cancer screening coverage in Europe. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 17 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Share of people aged 50 to 74 years who have been screened for colon and rectum cancer within the previous 2 years.